Document Type
Conference Proceeding
Publication Date
10-16-2025
First Page
20
Last Page
20
Recommended Citation
Ugradar S, Kostick DA, Spadaro J, Selva D, deSousa JL, Tumuluri K, et al. Safety, efficacy, and quality of life outcomes of subcutaneous lonigutamab (anti-IGF-1R): week 12 results from a phase 1/2 proof of concept study in patients with thyroid eye disease (TED). Presented at: American Society of Ophthalmic Plastic and Reconstructive Surgery 56th Annual Fall Scientific Symposium; 2025 Oct 16; Orlando, FL. Available from:https://asoprs.memberclicks.net/assets/Meetings/fall/ASOPRS_2025_Fall_Program.pdf

Comments
American Society of Ophthalmic Plastic and Reconstructive Surgery 56th Annual Fall Scientific Symposium, October 16-17, 2025, Orlando, FL